Heinsen Femke-Anouska, Knecht Henrik, Neulinger Sven C, Schmitz Ruth A, Knecht Carolin, Kühbacher Tanja, Rosenstiel Philip C, Schreiber Stefan, Friedrichs Anette K, Ott Stephan J
a Institute of Clinical Molecular Biology (ICMB); Christian-Albrechts-University (CAU) Kiel ; Kiel , Germany.
Gut Microbes. 2015 Jul 4;6(4):243-54. doi: 10.1080/19490976.2015.1062959.
Gut microbiota play a key role in the host's health system. Broad antibiotic therapy is known to disrupt the microbial balance affecting pathogenic as well as host-associated microbes. The aim of the present study was to investigate the influence of antibiotic paromomycin on the luminal and mucosa-associated microbiota at the DNA (abundance) and RNA (potential activity) level as well as to identify possible differences. The influence of antibiotic treatment on intestinal microbiota was investigated in 5 healthy individuals (age range: 20-22 years). All participants received the antibiotic paromomycin for 3 d. Fecal samples as well as sigmoidal biopsies were collected before and immediately after cessation of antibiotic treatment as well as after a recovery phase of 42 d. Compartment- and treatment status-specific indicator operational taxonomic units (OTUs) as well as abundance- and activity-specific patterns were identified by 16S rRNA and 16S rRNA gene amplicon libraries and high-throughput pyrosequencing. Microbial composition of lumen and mucosa were significantly different at the DNA compared to the RNA level. Antibiotic treatment resulted in changes of the microbiota, affecting the luminal and mucosal bacteria in a similar way. Several OTUs were identified as compartment- and/or treatment status-specific. Abundance and activity patterns of some indicator OTUs differed considerably. The study shows fundamental changes in composition of gut microbiota under antibiotic therapy at both the potential activity and the abundance level at different treatment status. It may help to understand the complex processes of gut microbiota changes involved in resilience mechanisms and on development of antibiotic-associated clinical diseases.
肠道微生物群在宿主健康系统中发挥着关键作用。众所周知,广泛使用抗生素治疗会破坏微生物平衡,影响致病微生物以及与宿主相关的微生物。本研究的目的是在DNA(丰度)和RNA(潜在活性)水平上研究抗生素巴龙霉素对肠腔和黏膜相关微生物群的影响,并确定可能存在的差异。在5名健康个体(年龄范围:20 - 22岁)中研究了抗生素治疗对肠道微生物群的影响。所有参与者接受了3天的抗生素巴龙霉素治疗。在抗生素治疗停止前、停止后立即以及42天的恢复期后收集粪便样本和乙状结肠活检组织。通过16S rRNA和16S rRNA基因扩增子文库以及高通量焦磷酸测序确定了特定区室和治疗状态的指示性操作分类单元(OTU)以及丰度和活性特异性模式。与RNA水平相比,肠腔和黏膜的微生物组成在DNA水平上存在显著差异。抗生素治疗导致微生物群发生变化,对肠腔和黏膜细菌的影响方式相似。确定了几个特定区室和/或治疗状态的OTU。一些指示性OTU的丰度和活性模式存在相当大的差异。该研究表明,在抗生素治疗下,不同治疗状态下肠道微生物群的组成在潜在活性和丰度水平上都发生了根本性变化。这可能有助于理解肠道微生物群变化在恢复机制以及抗生素相关临床疾病发展中所涉及的复杂过程。